Complement blockade with a C1 esterase inhibitor in paroxysmal nocturnal hemoglobinuria

Experimental Hematology

Volumn 42, Issue 10, 2014, Pages 857-861.e1

  DeZern, Amy E ^a,b   Uknis, Marc ^c   Yuan, Xuan ^b   Mukhina, Galina L ^b   Varela, Juan ^b   Saye, JoAnne ^c   Pu, Jeffrey ^b   Brodsky, Robert A ^a,b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ViroPharma Incorporated   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C1S INHIBITOR; COMPLEMENT COMPONENT C3; DECAY ACCELERATING FACTOR; ECULIZUMAB; CD59 ANTIGEN; CD59 PROTEIN, HUMAN; COMPLEMENT COMPONENT C5; MONOCLONAL ANTIBODY;

ADULT; ANTIGEN PRESENTING CELL; ARTICLE; BIOACCUMULATION; CLINICAL ARTICLE; COMPLEMENT ALTERNATIVE PATHWAY; COMPLEMENT DEPOSITION; COMPLEMENT INHIBITION; CYTOLYSIS; DRUG MECHANISM; ERYTHROCYTE; FEMALE; HUMAN; HUMAN CELL; MALE; MIDDLE AGED; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PROTEIN DEGRADATION; ANTAGONISTS AND INHIBITORS; BLOOD; COMPLEMENT CLASSICAL PATHWAY; COMPLEMENT LECTIN PATHWAY; DOSE RESPONSE; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; ERYTHROCYTE MEMBRANE; HEMOGLOBINURIA, PAROXYSMAL; IMMUNOLOGY; METABOLISM; PHYSIOLOGY; YOUNG ADULT;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD55; ANTIGENS, CD59; COMPLEMENT C1 INHIBITOR PROTEIN; COMPLEMENT C3; COMPLEMENT C5; COMPLEMENT PATHWAY, ALTERNATIVE; COMPLEMENT PATHWAY, CLASSICAL; COMPLEMENT PATHWAY, MANNOSE-BINDING LECTIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE; ERYTHROCYTE MEMBRANE; FEMALE; HEMOGLOBINURIA, PAROXYSMAL; HUMANS; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 84908384296     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2014.06.007     Document Type: Article

References (24)

1. Rosse W.F. Paroxysmal nocturnal hemoglobinuria as a molecular disease. Medicine 1997, 76:63-93.
2. Parker C., Omine M., Richards S., et al. Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood 2005, 106:3699-3709.
3. Brodsky R.A. Narrative review: paroxysmal nocturnal hemoglobinuria: the physiology of complement-related hemolytic anemia. Ann Intern Med 2008, 148:587-595.
4. Miyata T., Yamada N., Lida Y., et al. Abnormalities of PIG-A transcripts in granulocytes from patients with paroxysmal nocturnal hemoglobinuria. N Engl JMed 1994, 330:249-255.
5. Rollins S.A., Sims P.J. The complement-inhibitory activity of CD59 resides in its capacity to block incorporation of C9 into membrane C5b-9. J Immunol 1990, 144:3478-3483.
6. Hillmen P., Muus P., Duhrsen U., et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood 2007, 110:4123-4128.
7. Brodsky R.A., Young N.S., Antonioli E., et al. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood 2008, 111:1840-1847.
8. Rother R.P., Rollins S.A., Mojcik C.F., Brodsky R.A., Bell L., et al. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol 2007, 25:1256-1264.
9. Risitano A.M., Notaro R., Marando L., et al. Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab. Blood 2009, 113:4094-4100.
10. DeZern A.E., Dorr D., Brodsky R.A. Predictors of hemoglobin response to eculizumab therapy in paroxysmal nocturnal hemoglobinuria. Eur JHaematol 2013, 90:16-24.
11. Cai S., Dole V.S., Bergmeier W., et al. A direct role for C1 inhibitor in regulation of leukocyte adhesion. J Immunol 2005, 174:6462-6466.
12. Beinrohr L., Harmat V., Dobo J., Lorincz Z., Gal P., Zavodszky P. C1 inhibitor serpin domain structure reveals the likely mechanism of heparin potentiation and conformational disease. J Biol Chem 2007, 282:21100-21109.
13. Caliezi C., Zeerleder S., Redondo M., et al. C1-inhibitor in patients with severe sepsis and septic shock: beneficial effect on renal dysfunction. Crit Care Med 2002, 30:1722-1728.
14. Hack C.E., Ogilvie A.C., Eisele B., Jansen P.M., Wagstaff J., Thijs L.G. Initial studies on the administration of C1-esterase inhibitor to patients with septic shock or with a vascular leak syndrome induced by interleukin-2 therapy. Prog Clin Biol Res 1994, 388:335-357.
15. Nurnberger W., Heying R., Burdach S., Gobel U. C1 esterase inhibitor concentrate for capillary leakage syndrome following bone marrow transplantation. Ann Hematol 1997, 75:95-101.
16. de Zwaan C., Kleine A.H., Diris J.H., et al. Continuous 48-h C1-inhibitor treatment, following reperfusion therapy, in patients with acute myocardial infarction. Eur Heart J 2002, 23:1670-1677.
17. Jiang H., Wagner E., Zhang H., Frank M.M. Complement 1 inhibitor is a regulator of the alternative complement pathway. J Exp Med 2001, 194:1609-1616.
18. Brodsky R.A., Mukhina G.L., Li S., et al. Improved detection and characterization of paroxysmal nocturnal hemoglobinuria using fluorescent aerolysin. Am JClin Pathol 2000, 114:459-466.
19. Borowitz M.J., Craig F.E., DiGiuseppe J.A., et al. Guidelines for the diagnosis and monitoring of paroxysmal nocturnal hemoglobinuria and related disorders by flow cytometry. Cytometry B Clin Cytom 2010, 78:211-230.
20. Wilcox L.A., Ezzell J.L., Bernshaw N.J., Parker C.J. Molecular basis of the enhanced susceptibility of the erythrocytes of paroxysmal nocturnal hemoglobinuria to hemolysis in acidified serum. Blood 1991, 78:820-829.
21. Lindorfer M.A., Pawluczkowycz A.W., Peek E.M., Hickman K., Taylor R.P., Parker C.J. A novel approach to preventing the hemolysis of paroxysmal nocturnal hemoglobinuria: both complement-mediated cytolysis and C3 deposition are blocked by a monoclonal antibody specific for the alternative pathway of complement. Blood 2010, 115:2283-2291.
22. Hillmen P., Muus P., Roth A., et al. Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol 2013, 162:62-73.
23. Hillmen P., Elebute M., Kelly R., et al. Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria. Am J Hematol 2010, 85:553-559.
24. Risitano A.M., Notaro R., Luzzatto L., Hill A., Kelly R., Hillmen P. Paroxysmal nocturnal hemoglobinuria-hemolysis before and after eculizumab. N Engl J Med 2010, 363:2270-2272.